Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

820.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 820.41
Bid (Size) 779.00 (1)
Ask (Size) 830.20 (1)
Prev. Close 820.41
Today's Range 820.41 - 820.41
52wk Range 538.01 - 832.48
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023
 
Via Benzinga

Performance

YTD
+13.87%
+13.87%
1 Month
+8.26%
+8.26%
3 Month
+15.33%
+15.33%
6 Month
+19.58%
+19.58%
1 Year
+18.32%
+18.32%

More News

Read More
Analyst Ratings for Regeneron Pharmaceuticals
Via Benzinga
Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
Via Investor Brand Network
Why Shares of Regeneron Are Rising Thursday
Via The Motley Fool
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
Via The Motley Fool
Wall Street Has High Hopes for These 2 Nasdaq Stocks
Via The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
Via Investor's Business Daily
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Via Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Via Benzinga
US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears
Via Benzinga
Why Are Stocks Up Today?
Via InvestorPlace
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Via InvestorPlace
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Via Benzinga
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Via Benzinga
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
7 Value Stocks Worth Buying at These 52-Week Highs
Via InvestorPlace
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.